07 November 2011
A new cancer treatment has been developed that combines highly-targeted antibodies with light therapy, according to the journal Nature Medicine.
The treatment, called photoimmunotherapy, uses antibodies combined with a light-sensitive chemical (IR700). The antibodies are able to seek out specific cancerous cells and attach to them. A laser or other light source can then be used to activate the light-sensitive chemical to destroy the cancer cells.
The treatment was tested in mice that were implanted with cancerous tumours implanted. The scientists found that photoimmunotherapy reduced the size of the tumours when compared with mice who didn’t receive any treatment. They also found that the treated mice lived longer than those who received no treatment.
The scientists hope that this highly-selective therapy will lead to treatments that target and destroy only cancerous cells and not healthy tissue, unlike many current cancer treatments. They also suggest that it may be used as a monitoring and diagnostic tool for people with cancer.
Dr Virginia Warren, Assistant Medical Director for Bupa, commented: “Biological cancer therapies that use antibodies to target cancer cells and photodynamic therapy (light therapy) have been used separately with some success for several years. Bringing both therapies together as one treatment is an interesting concept and the results are encouraging.
“However, we mustn’t lose sight of the fact that this treatment has so far only been carried out in mice; no human trials have taken place yet. The researchers' work shows that this approach is worth more time and effort. Even if everything goes smoothly with its further research and development it is still several years away from being a feasible cancer treatment.”
Already a member? Find a Bupa approved cancer unit near you including breast, bowel and gynaecological specialist units.
Mitsunaga M,Ogawa M, Kosaka N, et al. Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nature Medicine 2011; online first. doi:10.1038/nm.2554